UNITED  STATES  SECURITIES  AND  EXCHANGE  COMMISSION
                              WASHINGTON,  DC  20549
                                   FORM  10-QSB



(MARK  ONE)

/X/     QUARTERLY  REPORT  PURSUANT  TO  13  OR  15(D)
        OF  THE  SECURITIES  EXCHANGE  ACT  OF  1934

FOR  THE  QUARTERLY  PERIOD  ENDED  SEPTEMBER  30,  2001

/ /     TRANSITION  REPORT  PURSUANT  TO  SECTION  13  OR  15(D)
        OF  THE  SECURITIES  EXCHANGE  ACT  OF  1934

FOR  THE  TRANSITION  PERIOD  FROM  _______________  TO  _______________

COMMISSION  FILE  NUMBER  000-28459

                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
             (EXACT  NAME  OF  REGISTRANT  AS  SPECIFIED  IN  ITS  CHARTER)

           DELAWARE                               59-2762023
---------------------------                  -----------------------------
(STATE  OR  OTHER  JURISDICTION  OF     (I.R.S.  EMPLOYER  IDENTIFICATION  NO.)
INCORPORATION  OR  ORGANIZATION)

                  43  WEST  33RD  STREET,  NEW  YORK,  NEW  YORK  10001
                  ---------------------------------------------
              (ADDRESS  OF  PRINCIPAL  EXECUTIVE  OFFICES)  (ZIP  CODE)

REGISTRANT'S  TELEPHONE  NUMBER,  INCLUDING  AREA  CODE  212-635-3334


INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS REQUIRED
TO BE FILED BY SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DURING
THE  PRECEDING  12  MONTHS  (OR  FOR SUCH SHORTER PERIOD THAT THE REGISTRANT WAS
REQUIRED  TO  FILE  SUCH  REPORTS)  AND  (2)  HAS  BEEN  SUBJECT  TO SUCH FILING
REQUIREMENTS  FOR  THE  PAST  90  DAYS.   YES  __X__  NO  ______.
                                                 -


INDICATE  THE  NUMBER  OF  SHARES OUTSTANDING IN EACH OF THE ISSUER'S CLASSES OF
COMMON  STOCK,  AS  OF  THE  LATEST  PRACTICABLE  DATE.

        CLASS
--------------------------

COMMON  SHARES,  $.0007  PAR  VALUE                   204,005,002
                                                -------------------------




<PAGE>



                                TABLE  OF  CONTENTS             PAGE
                                -----------------               ----



        CONSOLIDATED  BALANCE  SHEET  (UNAUDITED)                F-1

        CONSOLIDATED  STATEMENTS  OF  OPERATIONS  (UNAUDITED)    F-2

        CONSOLIDATED  STATEMENTS  OF  CASH  FLOWS  (UNAUDITED)   F-3

        NOTES  TO  THE  FINANCIAL  STATEMENTS                    F-4  -  F-11


<PAGE>



                       ADVANCED  PLANT  PHARMACEUTICALS,  INC
                       -----------------------------------
                                  BALANCE  SHEET
                            AS  OF  SEPTEMBER  30,  2001
                                   (UNAUDITED)

<TABLE>

<CAPTION>


                                     ASSETS


<S>                                                          <C>
CURRENT  ASSETS:
    CASH  AND  CASH  EQUIVALENTS                            $   691
    ACCOUNTS  RECEIVABLE                                        998
    INVENTORY                                                70,372
                                                        ------------
      TOTAL  CURRENT  ASSETS                                 72,061
                                                        ------------

      INTANGIBLE  ASSETS  (NET  OF  ACCUMULATED
             AMORTIZATION  OF  $170,373)                  2,355,861
      OTHER  ASSETS                                           4,602
                                                        ------------
                                                          2,360,463
                                                        ------------

      TOTAL  OTHER  ASSETS                             $  2,432,524
                                                        ============


                LIABILITIES  AND  SHAREHOLDERS'  EQUITY

  CURRENT  LIABILITIES:

    ACCOUNTS  PAYABLE                                   $   227,395
    ACCRUED  EXPENSES  PAYABLE                            2,419,007
    LOANS  PAYABLE                                          700,094
    DUE  TO  DISTRIBUTOR                                    103,500
                                                        ------------
      TOTAL  CURRENT  LIABILITIES                         3,449,996
                                                        ------------


  SHAREHOLDERS'  EQUITY:

    COMMON  STOCK,  $.0007  PAR  VALUE,  250,000,000
     SHARES  AUTHORIZED  AND  165,372,198  SHARES  ISSUED    115,761
    CAPITAL  IN  EXCESS  OF  PAR  VALUE                    7,032,977
    ACCUMULATED  DEFICIT                                  (8,166,210)
                                                         ------------
      TOTAL  SHAREHOLDERS'  EQUITY                        (1,017,472)
                                                         ------------
                                                        $  2,432,524
                                                         ============



                SEE  ACCOMPANYING  NOTES  TO  FINANCIAL  STATEMENTS.
                                      F-1

</TABLE>
<PAGE>
                         ADVANCED PLANT PHARMACEUTICALS, INC.
                      ------------------------------------
                            STATEMENTS OF OPERATIONS
                            ------------------------
                                   (UNAUDITED)
                                   -----------
<TABLE>
<CAPTION>

                                                    Three Months Ended          Nine Months Ended
                                                      September 30,              September 30,
                                                     2001         2000         2001         2000
                                                  ----------  ------------  ----------  ------------

<S>                                                     <C>         <C>           <C>         <C>
  Net Sales                                       $  15,585   $     2,202   $  32,825   $    11,263

  Cost of goods sold                                  6,983         7,270      20,530        52,964
                                                  ----------  ------------  ----------  ------------
      Gross profit                                    8,602        (5,068)     12,295       (41,701)
                                                  ----------  ------------  ----------  ------------

  Operating expenses:

    Research and development                            400     2,880,951       1,900     2,930,201
    General and administrative                      280,114       382,598     691,655     1,734,671
                                                  ----------  ------------  ----------  ------------
      Total operating expenses                      280,514     3,263,549     693,555     4,664,872
                                                  ----------  ------------  ----------  ------------

        Operating loss                             (271,912)   (3,268,617)   (681,260)   (4,706,573)

  Other expense (income)                                  -             -         655             -
                                                  ----------  ------------  ----------  ------------
      Loss before provision for income taxes       (271,912)   (3,268,617)   (681,915)   (4,706,573)

  Provision for income taxes                              -             -           -             -
                                                  ----------  ------------  ----------  ------------
      Net loss                                    $(271,912)  $(3,268,617)  $(681,915)  $(4,706,573)
                                                  ==========  ============  ==========  ============


  Loss per common share                           $   (0.00)  $     (0.03)  $   (0.00)  $     (0.04)
                                                  ==========  ============  ==========  ============



                See accompanying notes to financial statements.
                                      F-2

</TABLE>
<PAGE>

                      ADVANCED PLANT PHARMACEUTICALS, INC.
                      ------------------------------------
                            STATEMENTS OF CASH FLOWS
              FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2001 AND 2000
                                   (UNAUDITED)
<TABLE>
<CAPTION>

                                                           2001         2000
                                                        ----------  -------------
<S>                                                        <C>         <C>
  Cash Flows from Operating Activities:

    Net Loss from operations                            $(681,915)  $ (4,706,573)

    Adjustments to reconcile net loss from
     operations to net cash used by operating
     activities:

      Depreciation and amortization expense               128,375            685
      Services paid with common stock                     545,200        978,874
      Increase in accounts receivable and Other Assets     (2,653)             -
      Increase in Inventory                               (70,372)             -
      Increase in accounts payable                         85,007         49,634
      (Decrease) increase in accrued expenses            (121,550)     3,036,317
                                                        ----------  -------------
      Net cash used by operations                        (117,908)      (641,063)
                                                        ----------  -------------


  Cash Flows from Investing Activities:

    Purchase of computer equipment                              -         (1,000)
                                                        ----------  -------------
      Net cash used by investing activities                     -         (1,000)
                                                        ----------  -------------


  Cash Flows from Financing Activities:

    Proceeds from short-term loans payable                118,599        667,200
    Payments on short-term loans payable                        0        (25,009)
                                                        ----------  -------------
      Net cash provided by financing activities           118,599        642,191
                                                        ----------  -------------

  Net (decrease) in Cash and cash equivalents                 691            128

  Cash and cash equivalents at beginning of period              -         12,726
                                                        ----------  -------------
  Cash and cash equivalents at end of period            $     691   $     12,854
                                                        ==========  =============


  Supplemental Cash Flow Information:

    Cash Paid During the Period for:

      Interest                                                  -              -
                                                        ==========  =============
      Income Taxes                                              -              -
                                                        ==========  =============

    Information about Noncash Activities:
      Common stock issued to satisfy loans              $ 100,000   $          -
                                                        ==========  =============
      Common stock issued for services                  $ 435,200   $    978,874
                                                        ==========  =============

                See accompanying notes to financial statements.
                                      F-3
</TABLE>
<PAGE>
                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
                          NOTES  TO  FINANCIAL  STATEMENTS
                          -----------------------------
                               SEPTEMBER  30,  2001
                               ------------------
                                   (UNAUDITED)
                                   -----------

NOTE  1     BASIS  OF  PRESENTATION
            -----------------------

THE  ACCOMPANYING  UNAUDITED  FINANCIAL  STATEMENTS  OF  ADVANCED  PLANT
PHARMACEUTICALS,  INC.  ("APPI"  OR THE "COMPANY") AS OF SEPTEMBER 30, 2001 HAVE
BEEN  PREPARED  IN  ACCORDANCE WITH GENERALLY ACCEPTED ACCOUNTING PRINCIPLES FOR
INTERIM  INFORMATION.  ACCORDINGLY, CERTAIN INFORMATION AND FOOTNOTE DISCLOSURES
REQUIRED  UNDER  GENERALLY ACCEPTED ACCOUNTING PRINCIPLES HAVE BEEN CONDENSED OR
OMITTED  PURSUANT  TO  THE  RULES AND REGULATIONS OF THE SECURITIES AND EXCHANGE
COMMISSION.  IN THE OPINION OF MANAGEMENT, ALL ADJUSTMENTS OF A RECURRING NATURE
CONSIDERED  NECESSARY  FOR  A  FAIR  PRESENTATION OF THE RESULTS FOR THE INTERIM
PERIODS  PRESENTED  HAVE  BEEN  INCLUDED.  OPERATING RESULTS FOR THE NINE MONTHS
ENDED  SEPTEMBER 30, 2001 ARE NOT NECESSARILY INDICATIVE OF THE RESULTS THAT MAY
BE  EXPECTED  FOR  THE  ENTIRE  YEAR  OR  ANY  OTHER  PERIOD.

THESE  FINANCIAL  STATEMENTS  SHOULD  BE  READ  IN  CONJUNCTION WITH THE AUDITED
FINANCIAL  STATEMENTS  FOR  THE  YEAR  ENDED  DECEMBER  31,  2000.

NOTE  2     NATURE  OF  OPERATIONS
            ----------------------

APPI FOCUSES ON THE RESEARCH AND DEVELOPMENT OF PLANT BASED DIETARY SUPPLEMENTS.
THE  COMPANY  OWNS  THE  RIGHTS  TO  A  PROCESS,  WHICH UTILIZES WHOLE PLANTS TO
MANUFACTURE  ALL  NATURAL  DIETARY SUPPLEMENTS.  THE COMPANY INTENDS TO USE THIS
PROCESS  TO  MANUFACTURE  PRODUCTS THAT IT HOPES TO DISTRIBUTE WORLDWIDE THROUGH
VARIOUS  SALES  DISTRIBUTION  CONTRACTS.

THE COMPANY EXPECTS, IN THE NEAR TERM, TO FINANCE THESE EFFORTS THROUGH THE SALE
OF  ITS  COMMON  STOCK  UNTIL  SUCH TIME, IF EVER, THAT THE OPERATIONS ACHIEVE A
POSITIVE CASH FLOW.  THERE IS NO GUARANTEE THAT THE COMPANY WILL ACCOMPLISH THIS
GOAL.  SEE  NOTE  8,  "FINANCIAL  RESULTS  AND  LIQUIDITY."

NOTE  3     GOING  CONCERN
            --------------

MANAGEMENT BELIEVES THAT IT CAN CONTINUE TO OBTAIN ADDITIONAL CAPITAL.  HOWEVER,
IF  ADDITIONAL  FINANCING  IS NOT OBTAINED, THE COMPANY MIGHT BE FORCED TO CEASE
OPERATIONS.

SINCE  ITS  INCEPTION,  THE  COMPANY  HAS  HAD  SIGNIFICANT OPERATING LOSSES AND
WORKING  CAPITAL DEFICITS.  THE COMPANY'S CONTINUED EXISTENCE HAS BEEN DEPENDANT
ON  CASH PROCEEDS RECEIVED FROM THE SALE OF ITS COMMON STOCK AND THE WILLINGNESS
OF  VENDORS  TO  ACCEPT  STOCK  IN  LIEU  OF  CASH  PAYMENTS FOR THEIR SERVICES.
EMPLOYEES  HAVE  ALSO ACCEPTED DEFERRALS OF WAGE PAYMENTS.  THE COMPANY HOPES TO
REVERSE  THIS TREND BY GENERATING CASH INFLOWS THROUGH THE SALE OF NEW PRODUCTS.
TO  ACCOMPLISH  THIS  OBJECTIVE,  THE  COMPANY  WILL  REQUIRE WORKING CAPITAL TO
SATISFY  CURRENT OPERATING EXPENSES AND TO PRODUCE INVENTORY UNTIL SUCH TIME, IF
EVER,  THAT  THE  REVENUE  CYCLE  BEGINS  GENERATING  CASH.  THE  COMPANY'S PAST
ATTEMPTS  TO  ESTABLISH A MARKET FOR THEIR PRODUCTS HAS SO FAR BEEN UNSUCCESSFUL
AND  RESULTED  IN MINIMAL SALES.  THERE IS NO ASSURANCE THAT FUTURE EFFORTS WILL
RESULT  IN  A  MORE  FAVORABLE  OUTCOME.

                                       F-4

<PAGE>

                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
                          NOTES  TO  FINANCIAL  STATEMENTS
                          -----------------------------
                               SEPTEMBER  30,  2001
                               ------------------
                                   (UNAUDITED)
                                   -----------

NOTE  4     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES
            ----------------------------------------------

CASH  EQUIVALENTS
-----------------

FOR  PURPOSES  OF  THE STATEMENT OF CASH FLOWS, THE COMPANY CONSIDERS ALL HIGHLY
LIQUID  DEBT INSTRUMENTS PURCHASED WITH A MATURITY OF THREE MONTHS OR LESS TO BE
CASH  EQUIVALENTS.


OTHER  ASSETS
-------------
OTHER  ASSETS  CONSIST  OF  SECURITY  DEPOSITS  ($4,144)  AND COMPUTER EQUIPMENT
($458).

PATENTS  AND  TECHNOLOGY  PURCHASED ARE AMORTIZED ON A STRAIGHT-LINE METHOD OVER
THEIR  ECONOMIC  LIVES  AND  ARE  REVIEWED FOR IMPAIRMENT WHENEVER THE FACTS AND
CIRCUMSTANCES  INDICATE  THAT  THE  CARRYING  AMOUNT  MAY  NOT  BE  RECOVERABLE.

COMPUTER  EQUIPMENT  IS DEPRECIATED ON A STRAIGHT-LINE METHOD USING AN ESTIMATED
USEFUL  LIFE  OF  THREE  YEARS.

INVENTORY
---------

INVENTORIES  ARE  STATED AT THE LOWER OF COST OR MARKET.  ACTUAL COST IS USED TO
VALUE  RAW MATERIALS AND SUPPLIES.  INVENTORIES ALSO INCLUDE COSTS OF PROCESSING
AND  SHIPPING.

INTANGIBLE  ASSETS
------------------

INTANGIBLE ASSETS PRINCIPALLY REPRESENT THE EXCLUSIVE RIGHTS AND INTEREST TO THE
ALLERGY  AND  SINUS  FORMULATIONS  AND  A  THIRTEEN-  STEP  PROCESS  FOR  THE
MANUFACTURING  OF THE COMPANY'S PRODUCTS.  SUCH AMOUNTS ARE BEING AMORTIZED ON A
STRAIGHT-LINE  BASIS  OVER  15  YEARS.

RESEARCH  &  DEVELOPMENT  COSTS
-------------------------------

RESEARCH  AND  DEVELOPMENT  COSTS  ARE  EXPENSED  AS  INCURRED.

INCOME  TAXES
-------------

APPI  HAS  INCURRED SIGNIFICANT LOSSES FROM OPERATIONS.  THE COMPANY HAS ELECTED
NOT  TO  RECORD  ANY  TAX  BENEFITS  RELATING  TO  POTENTIAL  NET OPERATING LOSS
CARRYFORWARDS  DUE  TO  THE  UNCERTAINTY  OF  REALIZING  THOSE  BENEFITS.

THE  COMPANY  INTENDS  TO FOLLOW STATEMENT OF FINANCIAL ACCOUNTING STANDARDS NO.
109  (SFAS  109),  "ACCOUNTING  FOR INCOME TAXES" WHEN EITHER OPERATIONS ACHIEVE
PROFITABILITY OR THE REALIZATION OF NET OPERATING LOSS BENEFITS CAN MORE READILY
BE  MEASURED,  WHICHEVER  COMES  FIRST.



                                       F-5

<PAGE>
                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
                          NOTES  TO  FINANCIAL  STATEMENTS
                          -----------------------------
                               SEPTEMBER  30,  2001
                               ------------------
                                   (UNAUDITED)
                                   -----------

NOTE  4     SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES
            ----------------------------------------------
(CONTINUED)

EARNINGS  PER  SHARE
--------------------

STATEMENT  OF  FINANCIAL  ACCOUNTING  STANDARDS  ("SFAS") NO. 128, "EARNINGS PER
SHARE" DISCUSSES THE COMPUTATION AND PRESENTATION OF EARNINGS PER SHARE ("EPS").
BASIC  EPS, AS DEFINED BY SFAS NO. 128, IS COMPUTED BY DIVIDING INCOME AVAILABLE
TO  COMMON  SHAREHOLDERS  BY  THE  WEIGHTED-AVERAGE  NUMBER  OF  COMMON  SHARES
OUTSTANDING  FOR  THE  REPORTING  PERIOD,  IGNORING  ANY  POTENTIAL  EFFECTS  OF
DILUTION.  DILUTED  EPS  REFLECTS  THE  POTENTIAL  DILUTION  THAT WOULD OCCUR IF
SECURITIES,  OR  OTHER  CONTRACTS  TO  ISSUE  COMMON  STOCK,  WERE  EXERCISED OR
CONVERTED  INTO  COMMON  STOCK  THAT  THEN SHARED IN THE EARNINGS OF THE ENTITY.

THERE  WERE 5,500,000 COMMON STOCK OPTIONS OUTSTANDING AS OF SEPTEMBER 30, 2001.
AS  A  RESULT  OF THE LOSSES REPORTED IN THE PERIODS PRESENTED THESE OPTIONS, IF
EXERCISED,  WOULD  BE ANTIDILUTIVE.  ACCORDINGLY, ONLY BASIC EPS IS PRESENTED IN
THESE  FINANCIAL  STATEMENTS.  THE WEIGHTED-AVERAGE NUMBER OF SHARES USED IN THE
COMPUTATION  OF  PER  SHARE  DATA  WAS 163,263,502 AND 111,862,074 FOR THE THREE
MONTHS  ENDED  SEPTEMBER  30,  2001  AND 2000, RESPECTIVELY.  FOR THE NINE-MONTH
PERIODS  THEN  ENDED,  THE  WEIGHTED-AVERAGE NUMBER OF SHARES WAS 148,916,332 IN
2001  AND  110,057,560  IN  2000.

STOCK-BASED  COMPENSATION
-------------------------

APPI  HAS SATISFIED VARIOUS LOANS, TRADE PAYABLES, EMPLOYEE BACK-WAGES AND OTHER
LIABILITIES  THROUGH  THE  ISSUE  OF ITS COMMON STOCK.  THE COMPANY ACCOUNTS FOR
SUCH  STOCK-BASED COMPENSATION USING THE FAIR-VALUE METHOD AS PRESCRIBED BY SFAS
NO. 123, "ACCOUNTING FOR-STOCK-BASED COMPENSATION."  THE COMPANY HAS ALSO ISSUED
STOCK  OPTIONS TO KEY EMPLOYEES.  AS PERMISSIBLE UNDER SFAS NO. 123, THE COMPANY
ACCOUNTS  FOR STOCK OPTIONS USING THE INTRINSIC VALUE METHOD AS PRESCRIBED UNDER
ACCOUNTING  PRINCIPLES  BOARD  OPINION  NO.  25.

USE  OF  ESTIMATES
------------------

THE  PREPARATION  OF  FINANCIAL STATEMENTS IN CONFORMITY WITH GENERALLY ACCEPTED
ACCOUNTING  PRINCIPLES  REQUIRES  MANAGEMENT  TO MAKE ESTIMATES AND ASSUMPTIONS.
THESE  ESTIMATES  AND  ASSUMPTIONS  AFFECT  THE  REPORTED  AMOUNTS OF ASSETS AND
LIABILITIES,  THE  DISCLOSURE OF CONTINGENT LIABILITIES AND THE REPORTED AMOUNTS
OF  REVENUES  AND  EXPENSES.  ACTUAL  RESULTS COULD DIFFER FROM THESE ESTIMATES.







                                       F-6

<PAGE>
                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
                          NOTES  TO  FINANCIAL  STATEMENTS
                          -----------------------------
                               SEPTEMBER  30,  2001
                               ------------------
                                   (UNAUDITED)
                                   -----------

NOTE  5     CAPITAL  STOCK
            --------------

THE  COMPANY  IS  AUTHORIZED TO ISSUE 250 MILLION SHARES OF IT COMMON STOCK, PAR
VALUE  $.0007  PER  SHARE.  THE HOLDERS OF COMMON STOCK ARE ENTITLED TO ONE VOTE
FOR  EACH  SHARE  HELD  ON  ALL  MATTERS  TO  BE  VOTED  ON  BY  STOCKHOLDERS.

THE COMPANY IS ALSO AUTHORIZED TO ISSUE 5 MILLION SHARES OF PREFERRED STOCK, PAR
VALUE  $.0007  PER SHARE.  THERE IS CURRENTLY NO PREFERRED STOCK OUTSTANDING AND
THE  COMPANY  HAS  NO  CURRENT  PLANS  TO  ISSUE  PREFERRED  STOCK.

NOTE  6     LOANS  PAYABLE
            --------------

LOANS  PAYABLE  CONSISTS  OF  UNSECURED,  NON-INTEREST  BEARING SHORT-TERM LOANS
TYPICALLY  OF  LESS THAN THREE MONTHS DURATION.  THE LOAN AGREEMENTS PROVIDE THE
COMPANY  WITH  THE  OPTION  OF REPAYING THE LOANS WITH EITHER CASH OR RESTRICTED
SHARES  OF  THE  COMPANY'S  COMMON  STOCK.

NOTE  7     RELATED-PARTIES  TRANSACTIONS
            -----------------------------

ON  MARCH 15, 2000 THE COMPANY ENTERED INTO A TWO-YEAR EMPLOYMENT AGREEMENT WITH
DR.  LEONARD  BIELORY WHEREBY DR. BIELORY WILL SERVE AS THE COMPANY'S SCIENTIFIC
DIRECTOR  AND  ITS  CHAIRMAN  OF  THE BOARD OF DIRECTORS. UNDER THE TERMS OF THE
AGREEMENT,  THE  COMPANY  IS REQUIRED TO PAY DR. BIELORY WAGES OF $500 PER MONTH
FOR THE FIRST TWELVE MONTHS AND UP TO $2,500 PER MONTH THEREAFTER, CONTINGENT ON
THE  COMPANY  ACHIEVING  SPECIFIED NET PROFIT LEVELS.  UPON COMMENCEMENT OF THIS
AGREEMENT,  AND  EACH  JANUARY 1 THEREAFTER, THE COMPANY IS TO ISSUE DR. BIELORY
OPTIONS  TO  PURCHASE 750,000 SHARES OF THE COMPANY'S COMMON STOCK AS ADDITIONAL
COMPENSATION  UNDER  THIS AGREEMENT.  AS OF AUGUST 15, 2001, THE COMPANY HAS NOT
ISSUED  ANY  OF  THE  OPTIONS  REQUIRED  PER  THE AGREEMENT.  THE AGREEMENT ALSO
REQUIRED  THE  COMPANY  TO  ISSUE  DR.  BIELORY 225,000 RESTRICTED SHARES OF THE
COMPANY'S  COMMON  STOCK  AS  A  SIGNING  BONUS.  THE  FAIR  MARKET VALUE OF THE
COMPANY'S  STOCK  ON  MARCH  15,  2000 (THE DATE OF THIS AGREEMENT) WAS $.43 PER
SHARE.  THE  COMPANY  ACCRUED THE SHARES' AGGREGATE FAIR MARKET VALUE OF $96,750
AS ADDITIONAL COMPENSATION EXPENSE DURING THE FIRST QUARTER OF 2000.  THE SHARES
WERE  ISSUED  TO  DR.  BIELORY  DURING  APRIL  2000.

ON  JANUARY 22, 2001, THE COMPANY ENTERED INTO A CONSULTING AGREEMENT WITH SUMMA
CAPITAL,  INC.,  WHICH IS OWNED BY THE SON OF A CURRENT EMPLOYEE AND SHAREHOLDER
OF  THE  COMPANY.  IN  ACCORDANCE WITH THE AGREEMENT, SUMMA CAPITAL WILL PROVIDE
CONSULTING  SERVICES  IN  THE  AREA  OF  INVESTOR  RELATIONS,  PUBLIC RELATIONS,
MARKETING  AND  CAPITAL  MARKETS.  THE AGREEMENT IS RENEWABLE EVERY THREE MONTHS
BUT  MAY  BE  CANCELLED  BY  EITHER  PARTY  ON  A  MONTHLY  BASIS.




                                       F-7

<PAGE>
                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
                          NOTES  TO  FINANCIAL  STATEMENTS
                          -----------------------------
                               SEPTEMBER  30,  2001
                               ------------------
                                   (UNAUDITED)
                                   -----------

NOTE  7     RELATED-PARTIES  TRANSACTIONS
            -----------------------------
(CONTINUED)

COMPENSATION  PAYABLE  TO SUMMA CAPITAL UNDER THIS AGREEMENT INCLUDES $3,000 PER
MONTH  PAYABLE  IN  ADVANCE,  300,000 SHARES OF COMPANY STOCK AT THE END OF EACH
THREE-MONTH  PERIOD  AND A PERCENTAGE OF THE NET PROCEEDS OF ANY MONEY RAISED BY
THE  COMPANY  FROM  SOURCES  INTRODUCED  BY SUMMA CAPITAL.  ADDITIONALLY, AT THE
BEGINNING  OF  EVERY  THREE-MONTH  RENEWAL  PERIOD  SUMMA  CAPITAL IS TO RECEIVE
TWO-YEAR  WARRANTS CONVERTIBLE INTO 300,000 SHARES OF THE COMPANY'S COMMON STOCK
AND FIVE-YEAR WARRANTS TO PURCHASE AN ADDITIONAL 300,000 SHARES OF THE COMPANY'S
STOCK.  GENERAL  AND  ADMINISTRATIVE EXPENSES FOR THE THREE-MONTH AND NINE-MONTH
PERIODS ENDED SEPTEMBER 30, 2001, INCLUDES $34,000 AND $51,300, RESPECTIVELY, OF
EXPENSES  RELATING  TO  THIS  AGREEMENT  OF  WHICH  $5,700  HAS  BEEN PAID AS OF
SEPTEMBER  30,  2001.

ON  FEBRUARY  28,  2001,  THE  COMPANY  ENTERED  INTO  A LOAN AGREEMENT WITH SAM
BERKOWITZ,  AN  EMPLOYEE AND SHAREHOLDER OF THE COMPANY.  THE AGREEMENT IS FOR A
MAXIMUM  LOAN  AMOUNT  OF  $100,000 AND WAS INITIALLY DUE ON SEPTEMBER 30, 2001.
THE  COMPANY  HAS  BORROWED  $56,600  ON THIS LOAN WHICH IS STILL OUTSTANDING AT
SEPTEMBER  30,  2001.  THE  LOAN  IS INTEREST FREE AND INCLUDES THE OPTION TO BE
PAID  IN  COMPANY  STOCK.  IF  THE  LOAN  IS  PAID  IN  COMPANY STOCK, THE STOCK
CONVERSION  PRICE  IS  $.0165  PER  SHARE.

THE  COMPANY'S  PRESIDENT,  AND  HIS BROTHER, HAS ALSO LENT THE COMPANY MONEY AT
VARIOUS  TIMES  IN  THE  PAST.  OUTSTANDING  BALANCES  UNDER  THESE LOANS TOTALS
APPROXIMATELY  $80,000  AT  SEPTEMBER  30,  2001.

NOTE  8     FINANCIAL  RESULTS  AND  LIQUIDITY
            ----------------------------------

AS  OF  SEPTEMBER  30,  2001,  THE  COMPANY  HAD  NO  CASH  BALANCES.  SINCE ITS
INCEPTION,  THE COMPANY HAS HAD SIGNIFICANT OPERATING LOSSES AND WORKING CAPITAL
DEFICITS.  THE COMPANY'S CONTINUED EXISTENCE HAS BEEN DEPENDANT ON CASH PROCEEDS
RECEIVED  FROM  THE  SALE  OF ITS COMMON STOCK AND THE WILLINGNESS OF VENDORS TO
ACCEPT  STOCK  IN LIEU OF CASH PAYMENTS FOR THEIR SERVICES.  EMPLOYEES HAVE ALSO
ACCEPTED DEFERRALS OF WAGE PAYMENTS.  THE COMPANY HOPES TO REVERSE THIS TREND BY
GENERATING  CASH  INFLOWS  THROUGH THE SALE OF NEW PRODUCTS.  TO ACCOMPLISH THIS
OBJECTIVE, THE COMPANY WILL REQUIRE WORKING CAPITAL TO SATISFY CURRENT OPERATING
EXPENSES,  AND  TO  PRODUCE  INVENTORY, DURING THE INTERIM PERIOD PRECEDING SUCH
TIME,  IF  EVER,  THAT  THE  REVENUE  CYCLE  BEGINS  GENERATING  CASH.

TO  MARKET  AND  GENERATE  SALES  OF  ITS PRODUCTS, THE COMPANY HAS ENTERED INTO
VARIOUS  DISTRIBUTION  AGREEMENTS OVER THE YEARS.  AS OF SEPTEMBER 30 2001, NONE
OF  THE  DISTRIBUTION  AGREEMENTS  HAS  RESULTED  IN  SIGNIFICANT  SALES FOR THE
COMPANY.  THE  IMPACT  OF  ANY  CURRENT OR FUTURE DISTRIBUTION AGREEMENTS ON THE
COMPANY'S  CASH  FLOW  IS  UNCERTAIN.




                                       F-8

<PAGE>

                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
                          NOTES  TO  FINANCIAL  STATEMENTS
                          -----------------------------
                               SEPTEMBER  30,  2001
                               ------------------
                                   (UNAUDITED)
                                   -----------

NOTE  8     FINANCIAL  RESULTS  AND  LIQUIDITY
            ----------------------------------
(CONTINUED)

THERE  IS NO GUARANTEE THAT CASH GENERATED FROM NEW PRODUCT SALES WILL OCCUR, OR
BE  SUFFICIENT  TO FUND OPERATING COSTS WHICH CAN BE EXPECTED TO INCREASE AS THE
COMPANY "RAMPS UP" FOR MANUFACTURING AND DISTRIBUTION ACTIVITIES.  THERE ALSO IS
NO  ASSURANCE  THAT  THE  COMPANY WILL CONTINUE TO BE ABLE TO FINANCE OPERATIONS
THROUGH THE SALE OF ITS COMMON STOCK, THE EXCHANGE OF STOCK FOR SERVICES OR FROM
THE  PROCEEDS  OF  UNSECURED  LOANS  WITH  PRIVATE  LENDERS.


NOTE  9     FINANCIAL  ADVISOR  AND  INVESTMENT  BANKING  AGREEMENT
            -------------------------------------------------------

ON  FEBRUARY  17,  2000 THE COMPANY ENTERED INTO AN AGREEMENT WITH FIRST MADISON
SECURITIES,  INC. ("FMS") WHEREBY FMS WAS TO ACT AS CONSULTANT AND NON-EXCLUSIVE
FINANCIAL  ADVISOR  AND  INVESTMENT  BANKER  TO  THE  COMPANY IN CONNECTION WITH
STRATEGIC PLANNING, SECURITIES TRANSACTIONS, VALUATIONS, MERGERS & ACQUISITIONS,
ALTERNATIVE  FINANCING  STRUCTURES AND CAPITAL FORMATION.  FMS WOULD ALSO ACT AS
PLACEMENT  AGENT  FOR  THE  COMPANY.

AS  COMPENSATION  FOR  THESE  SERVICES,  THE  COMPANY  IS  REQUIRED TO ISSUE FMS
6,000,000  RESTRICTED  SHARES  OF  ITS COMMON STOCK AS FOLLOWS; 1,700,000 SHARES
UPON EXECUTION OF THE AGREEMENT, 1,700,000 SHARES WITHIN THREE MONTHS OF SIGNING
THE  AGREEMENT  AND 2,600,000 SHARES WITHIN SIX MONTHS OF SIGNING THE AGREEMENT.
THE  RESTRICTED  SHARES  WERE  TO BE REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION  TO  BECOME  FREE TRADING SHARES AS SOON AS POSSIBLE WITH FMS BEARING
ALL  REGISTRATION  COSTS.  GENERAL  AND  ADMINISTRATIVE  EXPENSES  FOR  THE
THREE-MONTHS ENDED MARCH 31, 2000 INCLUDES CONSULTING EXPENSE OF $663,000, WHICH
WAS  THE  AGGREGATE FAIR MARKET VALUE OF THE INITIAL 1,700,000 SHARES DUE TO FMS
ON  FEBRUARY  17,  2000.  THE  COMPANY  DISTRIBUTED THE INITIAL 1,700,000 SHARES
DURING  MAY  2000.

THE  COMPANY  IS  ALSO  REQUIRED TO PAY FMS A PLACEMENT FEE FOR ANY TRANSACTIONS
CONSUMMATED,  DIRECTLY  OR  INDIRECTLY,  THROUGH  FMS  DURING  THE  TERM  OF THE
AGREEMENT  OR  WITHIN TWO YEARS THEREAFTER.  THE PLACEMENT FEE WILL CONSIST OF A
PAYMENT  EQUAL  TO  10% OF THE GROSS PROCEEDS RAISED FROM THE SALE OF APPLICABLE
SECURITIES,  REIMBURSEMENT  OF NON-ACCOUNTABLE EXPENSES EQUAL TO 3% OF THE GROSS
PROCEEDS  FROM  THE  SALE OF ANY APPLICABLE SECURITIES PLUS WARRANTS TO PURCHASE
COMMON  STOCK  EQUAL  TO  10%  OF  THE APPLICABLE SHARES SOLD. ADDITIONALLY, THE
COMPANY WILL REIMBURSE FMS FOR ALL REASONABLE OUT-OF-POCKET EXPENSES INCURRED IN
THE  PERFORMANCE  OF  THIS  AGREEMENT,  UP  TO  A  MAXIMUM  OF  $25,000.

SERVICE  UNDER THIS AGREEMENT SHALL CONTINUE UNTIL TERMINATED BY EITHER PARTY BY
GIVING  THIRTY  DAYS  WRITTEN  NOTICE.  THIS  CONTRACT  WAS TERMINATED EFFECTIVE
DECEMBER  3,  2001.



                                       F-9

<PAGE>


                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
                          NOTES  TO  FINANCIAL  STATEMENTS
                          -----------------------------
                               SEPTEMBER  30,  2001
                               ------------------
                                   (UNAUDITED)
                                   -----------

NOTE  10     SALES  MANAGEMENT  AGREEMENT
             ----------------------------

ON  MARCH  16,  2001,  THE COMPANY ENTERED INTO AN AGREEMENT WHEREBY THE COMPANY
APPOINTED  NATIONAL BROKERS ASSOCIATES (NBA) AS THEIR EXCLUSIVE SALES MANAGEMENT
ORGANIZATION.  THE  AGREEMENT  IS  FOR  A ONE YEAR TERM.  COMPENSATION UNDER THE
AGREEMENT  INVOLVES  PERCENTAGE OF SALES VOLUME AND INCLUDES MINIMUM PAYMENTS OF
$5,000  PER  MONTH  OF  WHICH 80% CAN BE PAID WITH COMPANY STOCK AT A DISCOUNTED
CONVERSION  RATE.  THE  AGREEMENT CALLS FOR THE ISSUANCE OF ADDITIONAL SHARES OF
THE  COMPANY'S  STOCK  IF  CERTAIN  SALES  LEVELS  ARE  ACHIEVED.

NOTE  11     FINANCIAL  CONSULTING  AND  PUBLIC  RELATIONS  AGREEMENT
             --------------------------------------------------------

ON  JUNE  26,  2001,  THE  COMPANY  ENTERED  INTO  AN AGREEMENT WITH CONTINENTAL
MANAGEMENT GROUP, INC. (CMGI) WHEREBY CMGI WILL PROVIDE FINANCIAL CONSULTING AND
PUBLIC  RELATIONS  SERVICES  TO APPI.  THE AGREEMENT IS FOR A PERIOD OF ONE YEAR
COMMENCING  ON  JULY  1,  2001  BUT IS CANCELABLE BY EITHER PARTY ON THIRTY DAYS
WRITTEN  NOTICE.  COMPENSATION  UNDER  THIS  AGREEMENT  INCLUDES THE ISSUANCE OF
3,000,000  SHARES  OF  COMMON  STOCK OVER THE DURATION OF THE AGREEMENT IN EQUAL
MONTHLY  INSTALLMENTS.  ADDITIONALLY,  UPON  COMMENCEMENT  OF  SERVICES, 500,000
SHARES  OF  COMMON  STOCK,  AND OPTIONS TO PURCHASE 500,000 ADDITIONAL SHARES AT
$.025  PER  SHARE,  ARE  TO  BE  ISSUED  TO  CMGI.  THIS CONTRACT WAS TERMINATED
EFFECTIVE  DECEMBER  3,  2001.

NOTE  12     PRIOR  PERIOD  ADJUSTMENTS
             --------------------------

RECLASSIFICATION  OF  PURCHASE  OF  FORMULATION  AND  MANUFACTURING  PROCESS
----------------------------------------------------------------------------

ON  JULY 16, 1999, THE COMPANY ENTERED INTO A TECHNOLOGY PURCHASE AGREEMENT WITH
C.J.  LIEBERMAN  (BROTHER OF THE CURRENT PRESIDENT) WHEREBY THE COMPANY ACQUIRED
EXCLUSIVE  RIGHTS  AND  INTEREST  TO  A  THIRTEEN-STEP  PROCESS,  WHICH UTILIZES
VIRTUALLY  THE  WHOLE  OF  THE  NUTRIENTS  FOUND IN PLANTS TO MANUFACTURE HERBAL
DIETARY  SUPPLEMENTS.  THE  PURCHASE  PRICE  FOR THE PROCESS INCLUDES 18,000,000
SHARES  OF  THE  COMPANY'S  COMMON STOCK ISSUABLE IN TWO PHASES.  AS OF DECEMBER
2000,  NONE OF THE STOCK RELATED TO THIS AGREEMENT HAS BEEN ISSUED.  THE COMPANY
ACCRUED $1,440,000, IN ANTICIPATION OF ISSUING 12 MILLION SHARES THAT BECAME DUE
IN  2000 PER THE AGREEMENT.  THIS AMOUNT, WHICH REPRESENTS THE FAIR MARKET VALUE
OF  THE  STOCK  WHEN IT BECAME DUE UNDER THE AGREEMENT WAS INCLUDED IN "RESEARCH
AND  DEVELOPMENT"  COSTS  IN 2000 AND "ACCRUED EXPENSES PAYABLE" AT DECEMBER 31,
2000.

ON  FEBRUARY  28, 2000 THE COMPANY ENTERED INTO AN ASSET PURCHASE AGREEMENT WITH
DR.  LEONARD  BIELORY  (CHAIRMAN  OF THE BOARD OF DIRECTORS OF APPI) WHEREBY THE
COMPANY  ACQUIRED  THE  EXCLUSIVE  RIGHTS  AND  INTEREST  TO  ALLERGY  AND SINUS
FORMULATIONS  ("ASSETS").  THE  PURCHASE  PRICE  INCLUDES  OPTIONS  TO  PURCHASE
18,000,000  SHARES  OF THE COMPANY'S COMMON STOCK AT AN AGGREGATE EXERCISE PRICE
OF  $180.  THE  OPTIONS  ARE  TO  BE  ISSUED IN TWO PHASES.  THE FIRST PHASE WAS
COMPLETED  IN  2000  AND THE REQUIRED OPTIONS TO PURCHASE 12 MILLION SHARES WERE
ISSUED  DURING  THE  FOURTH  QUARTER  OF 2000.  THE FAIR VALUE OF THE 12 MILLION
SHARE  OPTIONS  WAS  $1,079,880  AND  WAS INCLUDED IN "RESEARCH AND DEVELOPMENT"
EXPENSE  IN  THE  2000  INCOME  STATEMENT.
                                      F-10

<PAGE>
                      ADVANCED  PLANT  PHARMACEUTICALS,  INC.
                      ------------------------------------
                          NOTES  TO  FINANCIAL  STATEMENTS
                          -----------------------------
                               SEPTEMBER  30,  2001
                               ------------------
                                   (UNAUDITED)
                                   -----------

NOTE  12     PRIOR  PERIOD  ADJUSTMENTS
             --------------------------
(CONTINUED)

DURING  THE  FOURTH  QUARTER  ENDING  DECEMBER 31, 2000, THE COMPANY EXPENSED AS
RESEARCH AND DEVELOPMENT, THE COMBINED COST OF $2,519,880 FOR THE ASSET PURCHASE
AGREEMENTS  WITH  DR. LEONARD BIELORY AND C.J. LIEBERMAN.  THE COMPANY CORRECTED
THE  ERROR  AND  CAPITALIZED  SUCH  COSTS  AS  INTANGIBLE  ASSETS,  SUBJECT  TO
AMORTIZATION.  THE EFFECT OF THE RESTATEMENT WAS TO REDUCE COSTS OF RESEARCH AND
DEVELOPMENT  AS  REPORTED  ON  DECEMBER  31,  2000  FROM  $2,615,630 TO $95,750.

ADDITIONALLY, THE COMPANY RECORDED APPROXIMATELY $42,000 OF AMORTIZATION FOR THE
SAME  PERIOD.  THE  EFFECT OF THE CORRECTION WAS TO REDUCE THE NET LOSS REPORTED
FOR  THE  YEAR  ENDED DECEMBER 31, 2000 FROM $4,778,734 ($.04 LOSS PER SHARE) TO
$2,300,854  ($.02  LOSS  PER  SHARE).

ADDITIONALLY,  THE COMPANY RECORDED APPROXIMATELY $42,000 OF AMORTIZATION DURING
THE  FIRST  QUARTER  ENDING  MARCH 31, 2001.  THE EFFECT ON THE CORRECTION IS TO
INCREASE  THE  LOSS  AS  ORIGINALLY  REPORTED  FROM  $173,787  TO  $215,787.


NOTE  13     SUBSEQUENT  EVENTS
             ------------------

IN  ADDITION  TO  THE  SHARES  THAT MAY POTENTIALLY BE ISSUED FOR THE AGREEMENTS
PREVIOUSLY DISCUSSED, THE COMPANY IS CURRENTLY CONSIDERING ISSUING APPROXIMATELY
8,705,000  SHARES  OF  COMMON  STOCK  TO  PAY  OFF  VARIOUS PAYABLES EXISTING AT
DECEMBER  30, 2001.  THE FAIR MARKET VALUE OF THESE SHARES AT SEPTEMBER 30, 2001
IS  APPROXIMATELY  $348,000.

IN  OCTOBER  2001,  THE COMPANY ISSUED APPROXIMATELY 38,676,372 COMMON SHARES TO
SATISFY  VARIOUS  DEBTS  AND  CONSULTING  AGREEMENTS.

NONE  OF  THE  SHARES  RELATING  TO  THESE  SUBSEQUENT  EVENTS  HAS BEEN USED TO
CALCULATE  EARNINGS  PER  SHARE  DATA  SINCE  THEY  WOULD  BE  ANTIDILUTIVE.














                                      F-11

<PAGE>


ITEM  1  -  LEGAL  PROCEEDINGS

     THE  REGISTRANT  HAS  RECEIVED  NOTICE  OF  OPPOSITION  TO  ITS  TRADEMARK
APPLICATION  FOR  THE  SINUSOL PRODUCT FROM THE OWNER OF A TRADEMARK FOR ANUSOL,
MANUFACTURED  BY  WARNER-LAMBERT  COMPANY.  THE  REGISTRANT  BELIEVES  THAT  ITS
PRODUCT AND TRADEMARK APPLICATION IS DISTINGUISHABLE FROM THE OPPOSER'S AND THAT
ANY  OPPOSITION  WILL  EVENTUALLY  BE  DENIED  AND ITS TRADEMARK GRANTED FOR THE
REGISTRANT'S  PRODUCT.

ITEM  2  -  CHANGES  IN  SECURITIES

     NONE

ITEM  3  -  DEFAULTS  UPON  SENIOR  SECURITIES

     NONE

ITEM  4  -  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY  HOLDERS

     NONE

ITEM  5  -  OTHER  INFORMATION

     NONE

ITEM  6  -EXHIBITS  AND  REPORTS  OF  FORM  8-K

     NONE


PURSUANT  TO  THE  REQUIREMENTS  OF  THE  SECURITIES  EXCHANGE  ACT OF 1934, THE
REGISTRANT  HAS  DULY  CAUSED  THIS  REPORT  TO  BE  SIGNED ON ITS BEHALF BY THE
UNDERSIGNED  THEREUNTO  DULY  AUTHORIZED.


ADVANCED  PLANT  PHARMACEUTICALS,  INC.

DAVID  LIEBERMAN,
PRESIDENT

DECEMBER  4,  2001